Epizyme, Inc. (NASDAQ:EPZM) Sees Large Growth in Short Interest

Epizyme, Inc. (NASDAQ:EPZMGet Rating) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 9,140,000 shares, a growth of 17.0% from the March 31st total of 7,810,000 shares. Based on an average trading volume of 3,140,000 shares, the short-interest ratio is presently 2.9 days.

A number of research firms have weighed in on EPZM. Zacks Investment Research lowered Epizyme from a “buy” rating to a “hold” rating and set a $1.75 target price on the stock. in a research note on Friday, March 4th. HC Wainwright reduced their price target on shares of Epizyme from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, March 2nd. Finally, StockNews.com started coverage on shares of Epizyme in a report on Thursday, March 31st. They set a “sell” rating for the company. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Epizyme has a consensus rating of “Hold” and a consensus price target of $8.19.

Shares of NASDAQ EPZM opened at $0.67 on Friday. Epizyme has a twelve month low of $0.62 and a twelve month high of $9.86. The firm has a market cap of $110.15 million, a PE ratio of -0.27 and a beta of 1.28. The business has a fifty day simple moving average of $1.08 and a two-hundred day simple moving average of $2.24.

Epizyme (NASDAQ:EPZMGet Rating) last announced its quarterly earnings results on Tuesday, March 1st. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.08). Epizyme had a negative net margin of 671.02% and a negative return on equity of 2,459.33%. The firm had revenue of $11.58 million for the quarter, compared to analysts’ expectations of $23.42 million. During the same quarter in the prior year, the business posted ($0.65) EPS. On average, equities research analysts anticipate that Epizyme will post -1.16 earnings per share for the current year.

Several large investors have recently made changes to their positions in EPZM. Kraematon Investment Advisors Inc. purchased a new stake in shares of Epizyme during the fourth quarter valued at about $28,000. Pinnacle Wealth Planning Services Inc. acquired a new position in Epizyme during the 4th quarter valued at about $31,000. Landscape Capital Management L.L.C. acquired a new position in Epizyme during the 4th quarter valued at about $40,000. Bayesian Capital Management LP purchased a new stake in Epizyme in the fourth quarter valued at about $40,000. Finally, Arizona State Retirement System boosted its holdings in Epizyme by 94.1% in the first quarter. Arizona State Retirement System now owns 37,398 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 18,134 shares in the last quarter. Institutional investors and hedge funds own 76.45% of the company’s stock.

About Epizyme (Get Rating)

Epizyme, Inc, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients.

See Also

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.